477 related articles for article (PubMed ID: 12717200)
1. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.
Nery JR; Nery-Avila C; Reddy KR; Cirocco R; Weppler D; Levi DM; Nishida S; Madariaga J; Kato T; Ruiz P; Schiff E; Tzakis AG
Transplantation; 2003 Apr; 75(8):1179-86. PubMed ID: 12717200
[TBL] [Abstract][Full Text] [Related]
2. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
3. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
4. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
[TBL] [Abstract][Full Text] [Related]
5. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
Holt D; Thomas R; Van Thiel D; Brems JJ
Arch Surg; 2002 May; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
[TBL] [Abstract][Full Text] [Related]
6. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ
Transplantation; 1999 Oct; 68(7):1058-61. PubMed ID: 10532552
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
10. Liver grafts from anti-hepatitis B core positive donors: a systematic review.
Cholongitas E; Papatheodoridis GV; Burroughs AK
J Hepatol; 2010 Feb; 52(2):272-9. PubMed ID: 20034693
[TBL] [Abstract][Full Text] [Related]
11. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis.
Joya-Vazquez PP; Dodson FS; Dvorchik I; Gray E; Chesky A; Demetris AJ; Shakil O; Fung JJ; Vargas HE
Transplantation; 2002 May; 73(10):1598-602. PubMed ID: 12042646
[TBL] [Abstract][Full Text] [Related]
12. Living donor liver transplantation from hepatitis B core antibody positive donors.
Celebi Kobak A; Karasu Z; Kilic M; Ozacar T; Tekin F; Gunsar F; Ersoz G; Yuzer Y; Tokat Y
Transplant Proc; 2007 Jun; 39(5):1488-90. PubMed ID: 17580169
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
[TBL] [Abstract][Full Text] [Related]
15. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
16. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors.
Dodson SF
Clin Transplant; 2000; 14 Suppl 2():20-4. PubMed ID: 10965960
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results.
Loss GE; Mason AL; Blazek J; Dick D; Lipscomb J; Guo L; Perrillo RP; Eason JD
Clin Transplant; 2001; 15 Suppl 6():55-8. PubMed ID: 11903388
[TBL] [Abstract][Full Text] [Related]
18. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine.
Jain A; Orloff M; Abt P; Kashyap R; Mohanka R; Lansing K; Kelley M; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3187-9. PubMed ID: 16213345
[TBL] [Abstract][Full Text] [Related]
19. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
[TBL] [Abstract][Full Text] [Related]
20. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
